Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.

Inclusion Criteria: * Aged over 18 * Patients with chronic heart failure class II-IV (NYHA)due to arterial hypertension * Patients clinically stable who required diuretic treatment * Patients with left ventricular hypertrophy diagnosed by echocardiogram * Patients without ischaemic cardiopathy or non recent disease * Signed Informed Consent Exclusion Criteria: * Heart Failure due to aortic stenosis or hypertrophic myocardiopathy * Recent coronary syndrome (less than 3 months) * Recent myocardial infarction (less than 6 months) * Unstable angor pectoris * Severe cardiac arrhythmia * Pregnancy or breastfeeding * Aldosterone antagonists (last 6 months) * Current loop diuretic treatment over study doses (torasemide \> 10mg/day furosemide \> 40 mg/day) * known hypersensitivity to study drugs * Liver disease (SGPT or AST \> twice upper normal limt) * Renal impairment (Serum creatinine \> 2,5mg/dl) * Insulin-dependent diabetes * Patient included in another simultaneous study * Lactose intolerance * Lithium Concomitant treatment * Chronic treatment with NSAIDs * Concomitant treatment with aminoglycoside antibiotics,etacrynic acid